2. Academic Validation
  3. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

  • Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):1038-46. doi: 10.1007/s00259-004-1571-4.
Lisa Bodei 1,  Marta Cremonesi,  Chiara Grana,  Paola Rocca,  Mirco Bartolomei,  Marco Chinol,  Giovanni Paganelli
Affiliations

Affiliation

  • 1 Nuclear Medicine Division, European Institute of Oncology, Milan, Italy.
PMID: 15150675 DOI: 10.1007/s00259-004-1571-4
Abstract

Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue (90)Y-[DOTA](0)-Tyr(3)-octreotide [(90)Y-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.

Figures
Products